---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-349127"
form_type: "8-K"
ticker: "SPRY"
cik: "0001671858"
company_name: "ARS Pharmaceuticals, Inc."
filed_at: "2026-08-13T20:03:18+00:00"
generated_at: "2026-08-13T20:04:11.502841+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# ARS Pharma Q2 2026: neffy revenue $26.2M, net loss $62.3M, cuts 2H expenses

## Summary
- Q2 neffy net product revenue $26.2M; total revenue $33.7M incl. $7.4M supply revenue.
- Net loss $62.3M ($0.63/share); cash $143.8M at June 30, 2026.
- 2H 2026 SG&A+R&D guided $114-126M (cash-based $100-110M); >40% cut in cash SG&A vs 1H.
- Meg Smith appointed CCO effective Aug 17, 2026; field sales expansion complete.
- Phase 2b CSU trial interim data expected Q1 2027; no approved on-demand CSU flare treatment.

## SEC filing metadata
- accession: 0001193125-26-349127
- form_type: 8-K
- ticker: SPRY
- cik: 0001671858
- company_name: ARS Pharmaceuticals, Inc.
- filed_at: 2026-08-13T20:03:18+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1671858/000119312526349127/0001193125-26-349127-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1671858/000119312526349127/spry-20260813.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-349127
- JSON: https://secwatch.observer/filing/0001193125-26-349127.json
- Plain text: https://secwatch.observer/filing/0001193125-26-349127.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.